Literature DB >> 7805653

Pathogenesis of pituitary Cushing's syndrome. Pituitary versus hypothalamic.

B M Biller1.   

Abstract

There has been a long-standing controversy as to whether Cushing's syndrome is primarily a hypothalamic disorder, with the pituitary simply responding to excess of CRH or other factors, or whether the defect lies at the level of the pituitary. Current data suggest that in nearly all cases, the tumor is clonal, implying a genetic defect at the level of the pituitary. The specific abnormalities underlying the development of corticotroph adenomas remain to be determined. It is certainly possible that the historical controversy has created an artificial dichotomy in our thinking about the pathogenesis of Cushing's syndrome and that hypothalamic factors may play a permissive role in the clonal expansion of a mutated pituitary cell. Finally, the finding of polyclonality in hyperplastic corticotroph tissue from a patient with an ectopic CRH-secreting tumor suggests there may be a more direct role for CRH in the pathogenesis of Cushing's syndrome in rare cases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7805653

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  3 in total

1.  Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease.

Authors:  N Sonino; G A Fava; F Fallo; A Franceschetto; P Belluardo; M Boscaro
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

Review 2.  Cushing's disease.

Authors:  Frederic Castinetti; Isabelle Morange; Bernard Conte-Devolx; Thierry Brue
Journal:  Orphanet J Rare Dis       Date:  2012-06-18       Impact factor: 4.123

3.  Usefulness of desmopressin testing to predict relapse during long-term follow-up in patients in remission from Cushing's disease.

Authors:  Alberto Giacinto Ambrogio; Massimiliano Andrioli; Martina De Martin; Francesco Cavagnini; Francesca Pecori Giraldi
Journal:  Endocr Connect       Date:  2017-10-10       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.